Kestra Medical Technologies, Ltd. (KMTS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | - | 8 | 28 | 60 | 95 | 107 |
| Operating profit | $m | -135 | -144 | ||||||
| Net profit | $m | -29 | -34 | - | -84 | -94 | -114 | -132 | -150 |
| EPS reported | $ | -2.43 | -2.67 | ||||||
| Operating cashflow per share | $ | -1.40 | -1.40 | ||||||
| Capex per share | $ | 0.60 | 0.60 | ||||||
| FCF per share | $ | -2.00 | -2.00 | ||||||
| Free cash flow | $m | -117 | -123 | ||||||
| Net debt | $m | -154 | -126 | ||||||
| Book value equity | $m | 260 | 222 | ||||||
| Book value per share | $ | 4.45 | 3.80 | ||||||
| Number of shares | m | 58.4 | 58.57 | ||||||
| DPS (TTM paid) | $ | 0.01 | 0.01 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.66 | 5.36 | ||||||
| P/S LTM | x | 11.28 | 11.17 | ||||||
| P/FCF LTM | x | -10.38 | -9.71 | ||||||
| EV/EBITDA LTM | x | -9.36 | -6.94 | ||||||
| EV/Sales LTM | x | 8.21 | 16.71 | ||||||
| Earnings Yield LTM | % | -11.76% | -8.04% | ||||||
| FCF Yield | % | -9.64% | -10.30% | ||||||
| Quality | |||||||||
| ROE | % | -50.69% | -58.76% | ||||||
| ROIC | % | -43.73% | -43.73% | ||||||
| Operating margin | % | -1.42% | -1.42% | ||||||
| Gross margin | % | +51.37% | +51.37% | ||||||
| FCF/Sales | % | -122.57% | -122.57% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +59.04% | +283.71% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.03% | 0.00% | ||||||
| Dividend Growth | % | -83.44% | -47.60% | ||||||
| Payout Ratio | % | -0.23% | -0.25% | ||||||
| FCF/Debt | x | -2.49 | -1.61 | ||||||
| Net Debt/EBITDA | x | 0.35 | 0.40 | ||||||
| EBIT/Net interest | x | -17.85 | -17.86 | ||||||
| Net debt/market cap | % | +3.53% | +2.60% | ||||||
| Net debt/Equity | x | -0.59 | -0.57 | ||||||
| Gross debt/equity | x | 0.18 | 0.34 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kestra Medical Technologies, Ltd. (KMTS)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free